Brief: Urogen Pharma Says CMS Issues Permanent J-Code For Urogen's Jelmyto
Nov 11 (Reuters) - Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA LTD - CMS ISSUES PERMANENT J-CODE FOR
UROGEN'S
JELMYTO EFFECTIVE JANUARY 1, 2021
* UROGEN PHARMA LTD - J-CODE IS EXPECTED TO REPLACE
PREVIOUSLY
ISSUED TEMPORARY C-CODE
* UROGEN - J-CODE TO FACILITATE REIMBURSEMENT IN HOSPITAL
OUTPATIENT, AMBULATORY SURGERY CENTER AND PHYSICIAN OFFICE
SETTINGS OF CARE FROM JAN. 1, 2021
Source text for Eikon: ID:nBw3Smldwa
Further company coverage: UR8.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors